
Pro-Dex (PDEX) Stock Forecast & Price Target
Pro-Dex (PDEX) Analyst Ratings
Bulls say
Pro-Dex is benefiting from strong execution in its core medical-device business, with fiscal Q1 2027 revenue rising 11% to $20.6 million and EPS of $0.92, both ahead of estimates. Its gross margin expansion to 33% from 29% reflects favorable product mix and operating leverage, while consistent growth over the past 10 years and a proprietary niche in regulated contract manufacturing support a durable earnings trajectory. The February 2026 acquisition of Advanced Precision Machining adds manufacturing capacity, technology, aerospace and defense exposure, and diversification away from a concentrated customer base, reinforcing the bullish fundamental case despite modest leverage.
Bears say
Pro-Dex is facing a difficult fundamental backdrop because demand for its technology, investor appetite for technology stocks, and broader consumer and industry sentiment can shift quickly, weakening visibility into sales and valuation support. Its outlook is further pressured by intense competition, regulatory risk, product risk, and the possibility of failing to achieve financial results, all of which are especially important given its reliance on powered surgical instruments for OEM customers. Broader macroeconomic and market conditions, along with changing economic conditions, add another layer of downside risk that can compress multiples and undermine earnings durability.
This aggregate rating is based on analysts' research of Pro-Dex and is not a guaranteed prediction by Public.com or investment advice.
Pro-Dex (PDEX) Analyst Forecast & Price Prediction
Start investing in Pro-Dex (PDEX)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Pro-Dex (PDEX) Forecast
Pro-Dex (PDEX) Analyst Forecast & Price Prediction
Start investing in Pro-Dex (PDEX)
Order type
Buy in
Order amount
Est. shares
0 shares